NLSUI OPAC header image
Amazon cover image
Image from Amazon.com

Intellectual property and biotechnology

By: Contributor(s):
Publication details: London Edward Elgar 2011Description: 561p xxiISBN:
  • 9781848442610
Subject(s): DDC classification:
  • 346.048000 RAI
Contents:
Table of contents Acknowledgements Introduction Arti K. Rai; PART I THE LAW AND ECONOMICS OF BIOTECHNOLOGY PATENTS: FIRST PRINCIPLESl A. Foundational Technologiesl 1. Edmund W. Kitch (1977), 'The Nature and Function of the Patent System'; 2. Robert P. Merges and Richard R. Nelson (1990), 'On the Complex Economics of Patent Scope'; B. Anti-commons; 3. Michael A. Heller and Rebecca S. Eisenberg (1998), 'Can Patents Deter Innovation? The Anti Commons in Biomedical Research'; 4. John P. Walsh, Ashish Arora and Wesley M. Cohen (2003), 'Working Through the Patent Problem'; 5. Fiona Murray and Scott Stern (2007), 'Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-commons Hypothesis'; 6. Chris Holman (2006) 'Clearing a Path Through the Patent Thicket'; C. Patents and Industrial Organization; 7. Ashish Arora and Robert P. Merges (2004), 'Specialised Supply Firms, Property Rights and Firm Boundaries'; PART II ADDRESSING TRANSACTION COSTS: THE ROLE OF THE UTILITY REQUIREMENT; 8. John M. Golden (2001), 'Biotechnology, Technology Policy, and Patentability: Natural Products and Invention in the American System'; PART III THE ROLE OF INSTITUTIONS: BIOTECHNOLOGY PATENTS AND THE FEDERAL CIRCUIT 9. Arti K. Rai (1999), 'Intellectual Property Rights in Biotechnology: Addressing New Technology'; 10. Dan L. Burk and Mark A. Lemley (2002), 'Is Patent Law Technology-Specific?'; PART IV PATENTABLE SUBJECT MATTER; 11. Kevin Emerson Collins (2007), 'Propertizing Thought'; PART V EXPERIMENTAL USE; 12. Janice M. Mueller (2001), 'No ''Dilettante Affair'': Rethinking the Experimental Use Exception to Patent Infringement for Biomedical Research Tools'; PART VI THE ROLE OF SECRECY AND PHYSICAL EXCLUDABILITY; 13. John P. Walsh, Wesley M. Cohen and Charlene Cho (2007), 'Where Excludability Matters: Material Versus Intellectual Property in Academic Biomedical Research'; PART VII COMMERCIALIZATION OF PUBLICLY FUNDED RESEARCH; 14. Richard Jensen and Marie Thursby (2001), 'Proofs and Prototypes for Sale: The Licensing of University Inventions'; 15. Arti K. Rai and Rebecca S. Eisenberg (2003), 'Bayh-Dole Reform and the Progress of Biomedicine'; PART VIII INTELLECTUAL PROPERTY AND CONSUMER ACCESS; 16. Robert Cook-Deegan, Subhashini Chandrasekharan and Misha Angrist (2009), 'The Dangers of Diagnostic Monopolies'; 17. Henry G. Grabowski, David B. Ridley and Kevin A. Schulman (2007), 'Entry and Competition in Generic Biologics'; Name Index;
Star ratings
    Average rating: 0.0 (0 votes)

Table of contents
Acknowledgements Introduction Arti K. Rai;

PART I THE LAW AND ECONOMICS OF BIOTECHNOLOGY PATENTS: FIRST PRINCIPLESl
A. Foundational Technologiesl
1. Edmund W. Kitch (1977), 'The Nature and Function of the Patent System';
2. Robert P. Merges and Richard R. Nelson (1990), 'On the Complex Economics of Patent Scope';
B. Anti-commons;
3. Michael A. Heller and Rebecca S. Eisenberg (1998), 'Can Patents Deter Innovation? The Anti Commons in Biomedical Research';
4. John P. Walsh, Ashish Arora and Wesley M. Cohen (2003), 'Working Through the Patent Problem';
5. Fiona Murray and Scott Stern (2007), 'Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-commons Hypothesis';
6. Chris Holman (2006) 'Clearing a Path Through the Patent Thicket';
C. Patents and Industrial Organization;
7. Ashish Arora and Robert P. Merges (2004), 'Specialised Supply Firms, Property Rights and Firm Boundaries';
PART II ADDRESSING TRANSACTION COSTS: THE ROLE OF THE UTILITY REQUIREMENT;
8. John M. Golden (2001), 'Biotechnology, Technology Policy, and Patentability: Natural Products and Invention in the American System';
PART III THE ROLE OF INSTITUTIONS: BIOTECHNOLOGY PATENTS AND THE FEDERAL CIRCUIT
9. Arti K. Rai (1999), 'Intellectual Property Rights in Biotechnology: Addressing New Technology';
10. Dan L. Burk and Mark A. Lemley (2002), 'Is Patent Law Technology-Specific?';
PART IV PATENTABLE SUBJECT MATTER;
11. Kevin Emerson Collins (2007), 'Propertizing Thought';
PART V EXPERIMENTAL USE;
12. Janice M. Mueller (2001), 'No ''Dilettante Affair'': Rethinking the Experimental Use Exception to Patent Infringement for Biomedical Research Tools';
PART VI THE ROLE OF SECRECY AND PHYSICAL EXCLUDABILITY;
13. John P. Walsh, Wesley M. Cohen and Charlene Cho (2007), 'Where Excludability Matters: Material Versus Intellectual Property in Academic Biomedical Research';
PART VII COMMERCIALIZATION OF PUBLICLY FUNDED RESEARCH;
14. Richard Jensen and Marie Thursby (2001), 'Proofs and Prototypes for Sale: The Licensing of University Inventions';
15. Arti K. Rai and Rebecca S. Eisenberg (2003), 'Bayh-Dole Reform and the Progress of Biomedicine';
PART VIII INTELLECTUAL PROPERTY AND CONSUMER ACCESS;
16. Robert Cook-Deegan, Subhashini Chandrasekharan and Misha Angrist (2009), 'The Dangers of Diagnostic Monopolies';
17. Henry G. Grabowski, David B. Ridley and Kevin A. Schulman (2007), 'Entry and Competition in Generic Biologics';
Name Index;